Methyl-CCNU versus methyl-CCNU and 5-fluorouracil in carcinoma of the large bowel.

Abstract

5-Flourouracil (5-FU) and methyl-CCNU have demonstrated separate sensitivities in carcinoma of the large bowel. This study was an attempt to see if methyl-CCNU versus methyl-CCNU plus 5-FU would demonstrate different responses in advanced colorectal carcinoma. Forty-nine patients have been evaluated, 14 receiving methyl-CCNU and 35 receiving 5-FU plus methyl-CCNU. One partial response has been seen with methyl-CCNU alone in a patient with liver metastasis. Thirteen partial responses have been noted in patients treated with the two-drug combination. There was a significant difference in the median survival of the responders versus the nonresponders for the two-drug group. Side effects were expected: nausea and vomiting, leukopenia, and thrombocytopenia. Plasma carcinoembryonic antigen and urine arylsulfatase were measured in all patients and correlated well with response.

• Authors: L E Posey, L R Morgan
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 61 Issue 8 Pg. 1453-8 (Nov 1977) ISSN: 0361-5960 [Print] United States
• PMID: 922750 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Carcinoembryonic Antigen
• Nitrosourea Compounds
• Semustine
• Arylsulfatases
• Fluorouracil

Topics

• Arylsulfatases (urine)
• Carcinoembryonic Antigen (analysis)
• Colonic Neoplasms (drug therapy)
• Drug Therapy, Combination
• Female
• Fluorouracil (adverse effects, therapeutic use)
• Humans
• Leukopenia (chemically induced)
• Male
• Middle Aged
• Nitrosourea Compounds (therapeutic use)
• Rectal Neoplasms (drug therapy)
• Semustine (adverse effects, therapeutic use)
• Thrombocytopenia (chemically induced)
• Vomiting (chemically induced)